Business Context and Reporting Period
LeonaBio, Inc. (LONA) filed a Current Report on Form 8-K on March 18, 2026, regarding a Special Meeting of stockholders held on the same date. The company is incorporated in Delaware and trades on The Nasdaq Capital Market. As of the record date (January 27, 2026), there were 9,335,913 shares of common stock outstanding. A quorum was established with 7,434,885 shares (approximately 79.63%) present or represented by proxy.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Equity Incentive Plan Approval: Stockholders approved the 2026 Equity Incentive Plan, replacing the terminated 2020 Equity Incentive Plan. The 2026 Plan authorizes the issuance of up to 5,700,000 shares, plus up to 1,300,000 additional shares from forfeited or expired awards under the prior plan. It includes an annual increase mechanism starting in fiscal year 2027.
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation. Authorized common shares increased from 90,000,000 to 400,000,000. Total authorized capital stock increased from 190,000,000 to 500,000,000.
- Warrant Exercises and Beneficial Ownership:
- Approved the issuance of 5,502,402 shares to Sermonix Pharmaceuticals, Inc. upon exercise of a pre-funded warrant.
- Approved the issuance of shares to Sermonix if the exercise results in beneficial ownership exceeding 19.99% of outstanding stock.
- Approved the issuance of shares to Perceptive Advisors LLC if the exercise results in beneficial ownership exceeding 19.99% of outstanding stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond standard corporate governance disclosures. The primary purpose of the filing is to report the successful completion of the Special Meeting and the resulting corporate actions.
Investor Verification Checklist
- Verify the exact number of shares issued to Sermonix Pharmaceuticals and Perceptive Advisors following the warrant exercises.
- Confirm the updated total number of authorized shares (400,000,000 common) in the company's charter.
- Review the specific terms of the 2026 Equity Incentive Plan (Exhibit 10.1) regarding vesting schedules and the annual share increase calculation.
- Monitor future filings for the impact of the new equity plan on dilution and share count.